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AbStrAct
The emergence of resistance to cisplatin is a serious drawback of cancer therapy. 
To help elucidate the molecular basis of this resistance, we examined matched ovarian 
cancer cell lines that differ in their DNA mismatch repair (MMR) status and the response 
to cisplatin. Checkpoint activation by cisplatin was identical in both lines. However, sensi‑
tive cells delayed S‑phase transition, arrested at G2/M and died by apoptosis. The G2/M 
block was characterized by selective disappearance of homologous recombination (HR) 
proteins, which likely resulted in incomplete repair of the cisplatin adducts. In contrast, 
resistant cells transiently arrested at G2/M, maintained constant levels of HR proteins and 
ultimately resumed cell cycle progression. The net contribution of MMR to the cisplatin 
response was examined using matched semi‑isogenic (HCT116±chr3) or strictly isogenic 
(293T‑La‑/+) cell lines. Delayed transition through S‑phase in response to cisplatin was 
also observed in the MMR‑proficient HCT116+chr3 cells. Unlike in the ovarian cell lines, 
however, both HCT116+chr3 and HCT116 permanently arrested at G2/M with an intact 
complement of HR proteins and died by apoptosis. A similar G2/M arrest was observed 
in the strictly isogenic 293T‑La‑/+ cells. This confirmed that although MMR undoubtedly 
contributes towards the cytotoxicity of cisplatin, it is only one of several pathways that 
modulate the cellular response to this drug. However, our data highlighted the impor‑
tance of HR to cisplatin cytotoxicity and suggested that HR status might represent a novel 
prognostic marker and possibly also a therapeutic target, the inhibition of which would 
substantially sensitize cells to cisplatin chemotherapy.
IntroductIon
Platinum-based	drugs	are	heavy	metal	complexes	containing	a	central	platinum	atom,	
which	are	frequently	used	in	the	treatment	of	human	malignancies.	Despite	their	wide-
spread	use,	side-effects	as	well	as	the	acquisition	of	resistance	seriously	limit	the	therapeutic	
efficacy	of	platinum	drugs	in	the	clinic.1	The	cytotoxic	activity	of	cisplatin	results	from	
interaction	of	the	highly	reactive	hydrated	form	of	the	drug	with	DNA,	preferentially	with	
the	N7	atoms	of	purine	residues.2	Formation	of	cisplatin-mediated	intra-	and,	to	a	lesser	
extent,	inter-strand	crosslinks	in	DNA	causes	distortions	of	the	double	helix,	which	inhibit	
replication,3	 transcription3,4	 and	 translation.5	DNA	 distortions	 caused	 by	 cisplatin	 are	
recognized	by	a	number	of	proteins	and	protein	complexes,6	such	as	the	MutSa	compo-
nent	of	the	mismatch	repair	(MMR)	system,7	the	high	mobility	group	proteins	HMG1	
and	HM	G2,
8	histone	H1,9	the	RNA	pol-I	binding	factor	hUBF10	and	the	TATA-binding	
protein	TBP.11	It	is	believed	that	binding	of	these	factors	to	cisplatin	adducts	may	inhibit	
or	limit	the	repair	of	such	adducts	by	the	nucleotide	excision	repair	(NER)	pathway.6,12
Disruption	of	the	DNA	structure	by	cisplatin-induced	interstrand	crosslinks	completely	
blocks	the	progression	of	the	replication	fork	and	lesions	of	this	type	have	to	be	processed	by	
homologous	recombination	(HR).13	On	the	other	hand,	1,2-intrastrand	crosslinks	gener-
ally	undergo	replication	bypass.14	However,	since	bypass	polymerases	are	error-prone,	such	
lesions	are	often	miscoding	and	prompt	the	generation	of	mismatches.15,16	Recognition	of	
such	compound	lesions	by	MutSa	likely	explains	the	involvement	of	DNA	mismatch	repair	
proteins17,18	and	may	underlie	the	observed	MMR-mediated	cisplatin	toxicity.19	Hence,	
cisplatin-resistant	cell	lines	may	have	a	MMR	defect,	which	is	most	frequently	linked	with	
mutations	in	the	hMSH2	or	hMLH1	genes,	or	with	the	epigenetic	silencing	of	the	latter	
locus.20-23	Experimental	evidence,	however,	showed	that	reexpression	of	silenced hMLH1	
could	rescue	the	drug	sensitivity	of	the	resistant	cell	lines	only	to	a	limited	extent,24	with	
p53-deficiency	apparently	playing	an	important	role	in	cisplatin	resistance.25	Additional	
metabolic	 changes	 were	 suggested	 to	 contribute	 to	 the	 acquisition	 of	 drug	 resistance.	
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Among	 those,	 an	 increase	 in	 glutathione	 (GSH)	 concentration,	
proportional	to	the	degree	of	cisplatin	resistance,	suggested	a	role	for	
GST	in	the	detoxification	processes.26	Moreover,	facilitated	excretion	
of	 cisplatin	 and	 enhanced	 repair	 of	 DNA	 adducts	 were	 proposed	
to	be	 other	 possible	mechanisms	of	 resistance.2	 Study	of	 the	 stress	
signals	triggered	by	cisplatin-induced	DNA	damage	have	implicated	
MAPK	 (ERK,	 JNK1/SAPK,	 p38MAPK)27-29	 and	 p53-dependent	
pathways,30	as	well	as	 the	transcription	factor	DNp63a,31	p73	and	
the	DNA	damage-activated	tyrosine	kinase	c-Abl.32
In	the	present	study,	we	studied	cell	cycle	progression	and	intracel-
lular	signaling	in	a	model	system	consisting	of	ovarian	cancer	cell	lines	
that	are	either	sensitive	or	resistant	to	cisplatin.	In	this	model,	bypass	
of	the	cisplatin-induced	G2/M	arrest	in	the	resistant	cells	appears	to	
depend	on	the	maintenance	of	an	intact	homologous	recombination	
apparatus,	which	in	turn	correlates	with	more	efficient	DNA	repair.	
To	investigate	the	net	contribution	of	DNA	mismatch	repair	to	cispl-
atin	resistance,	we	also	examined	semi-	or	strictly-isogenic	cell	lines	
that	are	proficient	or	deficient	in	the	repair	of	DNA	mismatches.	We	
found	 that	 the	 ability	 to	maintain	 functional	 homologous	 recom-
bination	 machinery	 was	 not	 linked	 to	 proficiency	 in	 MMR.	The	
implications	of	our	findings	for	cancer	therapy	are	discussed.
MAtErIALS And MEthodS
Cell lines.	The	human	embryonic	kidney	(HEK)	293T±La	cell	
line	 was	 derived	 from	 the	 hMLH1-deficient	 HEK293T	 cells	 by	
stable	transfection	with	a	vector	carrying	the	hMLH1	cDNA	under	
the	 control	 of	 the	 inducible	Tet-Off	 expression	 system.33	The	 cells	
were	 grown	 in	 DMEM	 with	 Eagle	 salts	 (Life	 Technologies,	 Inc.,	
Rockville,	 MD),	 supplemented	 with	 10%	 Tet-System	 approved	
fetal	 bovine	 serum	 (Clontech,	Palo	Alto,	CA),	 2	mM	L-glutamine	
(Life	 Technologies),	 100	 IU/ml	 penicillin,	 100	 mg/ml	 strepto-
mycin	 (Life	 Technologies),	 100	 mg/ml	 Zeocin	 (Invitrogen,	 San	
Diego,	 CA),	 and	 300	 mg/ml	 Hygromycin	 B	 (Roche	 Molecular	
Biochemicals,	Basel,	 Switzerland).	Downregulation	or	 induction	of	
hMLH1	(HEK293T-La-)	were	obtained	by	addition	or	removal	of	
50	ng/ml	Doxicyclin	(Dox	)	(Clontech),	respectively,	as	described.33	
The	 human	 colon	 cancer	 cell	 line	HCT116	 and	 its	 hMLH1-pro-
ficient	 subline	 HCT116+chr334	 were	 maintained	 in	 McCoy’s	 5A	
medium	(Life	Technologies)	with	10%	fetal	calf	serum	(FCS)	(Life	
Technologies),	 penicillin	 and	 streptomycin.	 In	 order	 to	 maintain	
the	 expression	 of	 chromosome	 3,	 400	mg/mL	G418	was	 added	 to	
the	medium.	The	human	ovarian	carcinoma	cell	 line	A2780	and	a	
cisplatin-resistant	 subline,	 CP70,	 were	maintained	 in	 RPMI	 1640	
containing	L-glutamine	and	supplemented	with	10%	FCS,	penicillin	
and	streptomycin.
For	synchronization	experiments,	cells	were	seeded	one	day	before	
treatment	and	2	mM	HU	was	added	for	16	h.	Cisplatin	was	added	
for	the	last	4	h	of	incubation	before	release	in	complete	medium.
Chemicals and antibodies.	 Cisplatin	 was	 obtained	 from	
Sigma	(St.	Louis,	MO)	and	dissolved	in	DMSO,	as	specified	by	the	
manufacturer.
Anti-hMLH1	 (554072),	 anti-hPMS2	 (556415)	 and	
anti-hRad51	 (551922)	 were	 from	 BD	 Pharmingen	 (S.	 Jose,	 CA);	
anti-hChk1-pSer345,	anti-hChk2-pThr68	and	anti-p95-Nbs1-pSer343	
were	 obtained	 from	 Cell	 Signaling	 Technology	 (Beverly,	 MA);	
anti-hChk1	 (611152)	 and	 anti-hMSH6	 (clone	 44,	 G70220)	 were	
purchased	 from	 BD	 Transduction	 Laboratories	 (S.	 Jose,	 CA);	
anti-hTFIIH	p89	(sc-19),	anti-p53	(Pab	1801),	anti-FANCD2	(FI17,	
sc-20022),	anti-BRCA1	(D-9,	 sc-6954),	anti-PCNA	(PC10,	 sc-56)	
and	 anti-b-tubulin	 (D-10)	 were	 from	 Santa	 Cruz	 Biotechnology	
(S.	Cruz,	CA);	anti-p95-Nbs1	(Ab398)	was	obtained	from	Abcam;	
anti-BRCA2	 (Ab-1)	was	 from	Calbiochem	 (Darmstadt,	Germany);	
anti-hChk2	(07-126),	anti-hCdk1	(06-966),	anti-gH2AX-pSer139	and	
anti-histone	H3-pSer10	 (06-570)	were	 from	Upstate	Biotechnology	
(Charlottesville,	 VA);	 anti-RPA-p34	 (Ab-3),	 anti-p21WAF1	 (Ab-1,	
OP64)	 and	 anti-hMRE11	 (Ab-1,	 PC388)	 were	 from	 Oncogene	
(S.	 Jose,	 CA);	 anti-ATM	 pSer1981	 was	 obtained	 from	 Rockland	
(Gilbertsville,	PA)	and	anti-ATM	was	kindly	provided	by	Stephen	P.	
Jackson	(Wellcome/CRC	Institute,	Cambridge,	UK).
Western blot analysis.	 Cellular	 proteins	 were	 extracted	 using	
ice-cold	 buffer	 A	 (50	 mM	 Tris-HCl	 pH	 7.5,	 120	 mM	 NaCl,	
20	mM	NaF,	1	mM	EDTA,	6	mM	EGTA,	15	mM	Na-pyrophosphate,	
0.5	mM	Na-orthovanadate,	 1	mM	benzamidine,	 0.1	mM	phenyl-
methylsulfonil	 fluoride	 (PMSF),	 1%	 Nonidet	 P-40).	 Protein	
concentration	 was	 determined	 using	 the	 Bio-Rad	 Protein	 Assay	
Reagent	(Bio-Rad,	Hercules,	CA).	Detection	of	proteins	by	Western	
blot	analysis	was	performed	following	separation	of	50	mg	whole	cell	
extracts	 on	 SDS-polyacrylamide	 gels.	 Proteins	 were	 transferred	 to	
a	Polyvinylidene	Fluoride	 (PVDF)	membrane,	 probed	with	 appro-
priate	 antibodies	 and	 immune	 complexes	 revealed	 using	 the	 ECL	
system	(Amersham-Pharmacia,	Uppsala,	Sweden).
Immunofluorescence.	Indirect	immunofluorescence	experiments	
were	 performed	with	 cells	 grown	 on	 acid-washed	 glass	 cover-slips.	
Fixation	was	done	in	ice-cold	methanol	(20	min	at	-20˚C).	Proteins	
were	 visualized	 by	 overnight	 incubation	 at	 4˚C	 using	 anti-gH2AX	
(1:100),	 anti-PCNA	 (1:200)	 and	 anti-H3-pS10	 (1:100).	 After	
washing,	the	cells	were	incubated	with	FITC-conjugated	anti-rabbit	
(1:750,	 Sigma)	 and	TR-conjugated	 anti-mouse	 antibodies	 (1:200,	
Abcam)	 for	 1	 h	 at	 37˚C.	 Nuclei	 were	 counterstained	 with	 DAPI	
(0.1mg/ml,	Sigma).	Images	were	captured	with	an	Olympus	(IX81)	
fluorescence	microscope.
MTT assay.	Two	thousand	cells/well	were	seeded	in	96-well	plates	
one	day	before	treatment.	Cells	were	treated	with	cisplatin	for	4	h,	
the	drug	was	removed	and	cells	were	incubated	for	five	days.	Upon	
addition	 of	 the	 MTT	 solution	 (0.5	 mg/ml)	 (Sigma),	 plates	 were	
incubated	 for	 4-5	 h	 at	 37˚C.	One	 volume	 of	 lysis	 solution	 (20%	
SDS,	50%	dimethylformamide	pH	<4.7)	was	added	and	the	plates	
were	 incubated	 overnight	 at	 37˚C.	 The	 solubilized	 formazan	 was	
quantified	at	570	nm	using	a	Versamax	microplate	reader	(Molecular	
Devices,	Sunnyvale.	CA).	Optical	density	values	were	plotted	against	
the	 logarithm	 of	 cisplatin	 concentrations	 and	 IC50	 values	 were	
calculated	from	the	regression	curve.
Cell cycle analysis.	Cells	were	harvested	 at	 the	 indicated	 times,	
counted,	washed	with	PBS,	 fixed	with	70%	ethanol	and	 stored	up	
to	one	week	at	4˚C.	Cells	were	then	washed	with	PBS,	incubated	in	
PBS	containing	RNase	A	(100	mg/ml,	Sigma)	for	1	h	at	37˚C,	stained	
with	propidium	iodide	(20	mg/ml,	Sigma)	and	 incubated	on	 ice	 in	
the	 dark	 for	 30	min.	DNA	 content	 was	 analyzed	 using	 a	Coulter	
FC500	Flow	Cytometer	(Beckman	Coulter	Inc.,	Fullerton,	CA)	and	
quantification	was	performed	with	the	software	WinMDI	2.8.
Quantification of S‑phase transition.	 Cells	 were	 seeded	 in	
six-well	plates	 at	density	6	x	103	 cells/well	 and	grown	 in	 complete	
medium	for	24	h.	HU-synchronization	and	cisplatin	treatment	were	
performed	as	indicated	above.	One	hour	before	harvesting	cells	were	
treated	with	10	mM	BrdU	(Roche,	Cell	Proliferation	ELISA,	BrdU	
colorimetric,	Cat.	No.	1	647	229)	and	cells	were	processed	according	
to	 the	 instructions	 of	 the	 manufacturer.	 BrdU	 incorporation	 into	
nascent	DNA	was	quantified	at	370	nm	using	492	nm	as	reference	
wavelength	in	a	Versamax	microplate	reader.
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The response of MMR‑proficient and 
‑deficient cell lines to cisplatin.	 A2780	 is	 a	
human	 ovarian	 cancer	 cell	 line,	 from	which	 a	
cisplatin	 resistant	 sub-line	 (CP70)	was	derived	
through	exposure	to	increasing	drug	concentra-
tions.35	 These	 matched	 cell	 lines	 are	 among	
the	 few	 examples	 of	 cells	 of	 ovarian	 origin	
displaying	 an	 altered	 MMR	 status.36	 A2780	
cells	 are	MMR-proficient,	 whereas	 CP70	 cells	
are	 MMR-deficient	 as	 a	 result	 of hMLH1	
gene	 promoter	 hypermethylation	 and	 conse-
quent	 lack	 of	MLH1	 expression.24	 In	 our	 cell	
viability	 assays,	 the	 CP70	 cells	 were	 ~10-fold	
more	resistant	to	killing	by	cisplatin	(Fig.	1A),	
as	 reported	 by	 others.37	 Clonogenic	 assays	
showed	that	matched	pairs	of	MMR-proficient	
and	 -deficient	 cells,	 such	 as	 the	 semi-isogenic	
HCT116±chr3	 cells,	 displayed	 only	 ~1.5-fold	
sensitivity	 differences	 to	 cisplatin.38	 Likewise,	
in	the	strictly	isogenic	HEK	293T-MutLa-/La+	
cells,	 which	 differ	 solely	 in	 the	 expression	 of	
hMLH1,33,39,40	 the	 sensitivity	 difference	 to	
cisplatin	was	~2-fold	(293T-MutLa-	IC50	=	5.3	
±	0.25	mM;	293T-MutLa+	IC50	=	2.65	±	0.35	
mM;	 and	 19).	These	 results	 indicated	 that	 the	
larger	difference	in	cisplatin	sensitivity	observed	
in	the	A2780/CP70	system	as	compared	to	the	
isogenic	cell	 lines	 is	 likely	attributable	 to	 traits	
other	than	their	MMR	status,	the	acquisition	of	
which	may	have	been	facilitated	by	inactivation	
of	 the	 MMR	 system	 during	 clonal	 selection.	
Indeed,	it	has	been	proposed	that	genetic	insta-
bility	facilitates	the	acquisition	of	drug	resistance	
through	the	selection	of	adaptive	mutations	that	
occur	more	copiously	 in	DNA	repair-defective	
cells.41	In	the	hope	of	identifying	the	pathways	
responsible	for	the	increased	cisplatin	resistance	
of	 the	 CP70	 cells,	 we	 decided	 to	 search	 for	
differences	in	the	response	of	the	A2780	and	the	
CP70	cells	to	cisplatin	treatment.
Flow	cytometric	analyses	of	A2780	and	CP70	
cells	 treated	 with	 15	 mM	 cisplatin,	 which	 is	
equivalent	to	IC90	of	the	former	cells	(Fig.	1A),	
Figure 1. Cisplatin response in A2780 and CP70 
cells. (A) The response of A2780 and CP70 to 
increasing doses of cisplatin (CDDP) was determined 
in an MTT assay after 72 h. (B) Flow cytometric analy‑
ses of A2780 and CP70 cells treated with 15 mM 
cisplatin for the indicated times. (C and D) Western 
blot analyses of total cell extracts derived from the 
cells shown in panel B. IR (10 Gy), HU (2 mM) or UV 
(20 J/m2) were used as positive controls to assess the 
functionality of the checkpoint. TFIIH (panel C) and 
b‑tubulin (panel D) were used as loading controls. (E) 
Assessment of H2AX phosphorylation and nuclear 
foci formation in A2780 and CP70 cells treated with 
15 mM cisplatin for the indicated times. The antibody 
displayed a certain degree of diffused background 
staining in untreated cells, though foci appeared 
clearly in cisplatin‑treated cells.
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indicated	 that	 the	 treatment	 affected	 progression	 through	 the	 cell	
cycle	in	both	cell	lines	(Fig.	1B).	The	response	of	the	MMR-proficient	
A2780	 cells	 was	 characterized	 by	 a	 delayed	 transition	 through	
S-phase	 (Fig.	1B,	12–24	h)	prior	 to	G2	 arrest	 (Fig.	1B,	48	h)	 and	
triggering	 of	 apoptosis,	 as	 indicated	 by	 the	 presence	 of	 a	 sub-G1	
peak	 in	 the	 flow	 cytometric	 profile	 (Fig.	 1B,	 72	 h).	On	 the	 other	
hand,	 the	 cisplatin-resistant	 CP70	 cells	 transited	 through	 S-phase	
with	only	a	slight	delay	and	accumulated	at	G2/M	(Fig.	1B,	24	h).	
Moreover,	at	later	time	points,	the	CP70	cells	were	able	to	bypass	the	
G2-block	and	resume	cell	 cycle	progression	(Fig.	1B,	48–72	h).	To	
define	the	point	at	which	the	A2780	and	CP70	arrested	in	response	
to	cisplatin,	we	examined	phosphorylation	of	histone	H3,	which	is	
indicative	 of	 the	 extent	 of	 chromatin	 condensation	 in	 late	G2	 and	
mitosis.	Western	blot	analyses	showed	that	the	A2780	cells	did	not	
contain	phosphorylated	histone	H3	at	any	time,	thus	indicating	that	
the	cells	were	arrested	in	late	S-/early	G2-phase.	On	the	contrary,	the	
CP70	cells	displayed	 a	 clear	 signal	 for	 the	phosphorylated	histone,	
thus	confirming	that	these	cells	reached	the	G2/M	transition	of	the	
cell	cycle	(Fig.	1C).
We	 then	 examined	 the	pattern	of	 cisplatin-induced	 signaling	 in	
A2780	and	CP70	cells.	A2780	displayed	rapid	 stabilization	of	p53	
and	transcriptional	induction	of	p21Waf1,	whereas	in	CP70	the	p53	
response	 was	 delayed	 and	 of	 smaller	 magnitude	 (Fig.	 1C).	 More	
importantly,	no	p21Waf1	was	detected	in	CP70	(Fig.	1C).	This	was	
likely	 due	 to	 lack	 of	 gene	 induction	 caused	 by	 the	 nonfunctional	
p53	 protein	 expressed	 in	 CP70	 cells,42	 rather	 than	 the	 result	 of	
protein	 degradation	 consequent	 to	 mitotic	 arrest,43	 since	 p21Waf1	
could	 not	 be	 detected	 at	 any	 time	 prior	 to	 the	 G2/M	 arrest	 or	
following	 reentry	 into	G1	 (Fig.	 1B	 and	C).	These	 data	 confirmed	
that	the	cisplatin-induced	p53	stabilization	in	CP70	cells	represents	
a	 nonproductive	 response.	 Checkpoint	 pathways	 were	 triggered	 in	
an	identical	manner	in	both	ovarian	cancer	cell	lines	(Fig.	1D).	This	
response	 consisted	 in	 activation	 of	 ATM	 and	 phosphorylation	 of	
its	 downstream	 targets	 CHK2,	 BRCA1	 and	 FANCD2.	The	 latter	
migrated	in	SDS-PAGE	as	a	doublet,	with	the	slower	migrating	band	
likely	 corresponding	 to	 mono-ubiquitylated	 FANCD2.44	 In	 this	
setting,	CHK2	displayed	 long-lasting	 activation,	which	 is	 attribut-
able	to	secondary	lesions	resulting	from	stalled	replication	at	sites	of	
damage.	On	the	other	hand,	CHK1	was	only	transiently	activated.	
According	to	their	slower	progression	through	S-phase	(Fig.	1B),	the	
A2780	cells	displayed	a	slightly	more	pronounced	phosphorylation	of	
NBS1	at	12–24	h,	as	compared	to	the	CP70	line	(Fig.	1D).	Despite	
these	 similarities,	net	differences	 in	 the	 signaling	pattern	of	A2780	
and	CP70	cells	could	be	observed	at	later	times	after	DNA	damage.	
In	G2-arrested	A2780	cells,	BRCA1,	BRCA2,	FANCD2	and	RAD51	
underwent	complete	degradation	(Fig.	1D,	48	h	and	72	h)	and	the	
disappearance	of	these	proteins	paralleled	the	activation	of	an	apop-
totic	response,	as	indicated	by	the	appearance	of	the	sub-G1	peak	in	
the	flow	cytometric	profile	(Fig.	1B,	48–72	h).	In	contrast	RAD51,	
BRCA1,	BRCA2	and	FANCD2	were	expressed	at	all	times	in	CP70	
cells.	 The	 ability	 of	 CP70	 cells	 to	 resume	 progression	 through	
the	 cell	 cycle	 correlated	with	 a	 decrease	 in	 the	 size	 of	 gH2AX	 foci	
(Fig.	1E,	72	h),	which	may	be	 indicative	of	 either	 a	greater	 ability	
to	repair	DNA	damage	in	these	cells	or	of	reduced	induction	of	the	
DNA	repair	response	consequent	to	the	absence	of	MMR.
Figure 2. Cisplatin response in HCT116 and HCT116+chr3 cells. (A) Flow cytometric analysis of the semi‑isogenic, MMR‑proficient (HCT116+chr3) and 
MMR‑deficient (HCT116) cells treated with 15 mM cisplatin for the indicated times. (B and C) Western blot analyses of total cell extracts derived from the 
cells shown in (A).
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These	data	showed	that	the	pattern	of	activation	of	signaling	path-
ways	 in	 the	 sensitive	and	resistant	cells	was	very	 similar	during	 the	
first	48	h,	indicating	that	the	presence	of	DNA	damage	was	equally	
well	 detected	 and	 signaled.	 However,	 the	 maintenance	 of	 intact	
homologous	 recombination	 machinery	 likely	 conferred	 a	 selective	
advantage	to	the	CP70	cells	in	bypassing	the	G2/M	arrest.
The Response to Cisplatin in Isogenic Systems.	 Loss	 of	DNA	
mismatch	 repair	 leads	 to	 genomic	 instability	 through	 an	 increased	
frequency	 of	 sporadic	 mutations	 in	 both	 coding	 and	 noncoding	
regions.	 To	 assess	 the	 role	 of	 MMR	 proteins	 in	 cisplatin-induced	
signaling	 more	 closely,	 we	 studied	 the	 drug	 response	 in	 matched	
pairs	of	MMR-deficient	and	-proficient	cell	lines.	In	HCT116+chr3,	
the	 lack	of	MLH1	in	the	colon	cancer	cell	 line	HCT116	has	been	
complemented	 by	 transfer	 of	 an	 additional	 copy	 of	 chromosome	
3,	 which	 carries	 the	 MLH1	 gene.34	 We	 found	 that	 treatment	 of	
asynchronous	 HCT116	 and	 HCT116+chr3	 cells	 with	 a	 concen-
tration	 of	 cisplatin	 equivalent	 to	 IC50	 for	 the	 proficient	 cell	
line,38	resulted	in	a	similar	response	in	the	two	cell	lines,	which	was	
Figure 3. Cisplatin‑treated HCT116+chr3 and HCT116 cells arrest at different points in the cell cycle. (A) HU‑synchronized HCT116±chr3 cells, untreated or 
treated with 15 mM cisplatin for the last 4 h of synchronization. After release, cell cycle progression was assessed by flow cytometry at the indicated times. 
(B) Western blot analyses of total cell extracts derived from the cells shown in panel A. (C) Indirect immunofuorescence of S‑phase and DNA damage mark‑
ers in HCT116+chr3 and HCT116 cells. Cells synchronized as in A were fixed and stained with antibodies against PCNA (red) or phosphorylated H2AX 
(green). Nuclei were stained with DAPI. The corresponding flow cytometric profiles of HCT116+chr3 and HCT116 cells at 20 h post‑treatment are shown.
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characterized	by	a	G2	arrest	24	h	post-treat-
ment	 (Fig.	 2A).	 The	 overall	 pattern	 of	
protein	 phosphorylation	 observed	 in	
response	 to	 cisplatin	 also	 seemed	 to	 be	
similar	 in	 the	 two	 cell	 lines	 (Fig.	 2B	 and	
C).	 In	 both	 cases,	 the	 loss	 of	 viability	
that	 ensued	 upon	 prolonged	 arrest	 in	G2,	
was	 paralleled	 by	 degradation	 of	 DNA	
repair	 proteins	 (Fig.	 2B,	 72	 h).	However,	
closer	analysis	of	the	flow	cytometric	profile	
possibly	 revealed	 a	 slightly	 larger	 S-phase	
population	 in	 the	 HCT116+chr3	 cells	 at	
the	 24	 and	 48	 h	 time	 points	 (Fig.	 2A).	
In	 order	 to	 examine	 the	 cisplatin-induced	
S-phase	 delay	 observed	 in	 the	 mismatch	
proficient	HCT116+chr3	more	closely,	we	
analyzed	a	synchronized	population	of	cells.	
Cells	 synchronized	 at	 the	 G1/S	 boundary	
with	hydroxyurea	 (HU)	were	 treated	with	
cisplatin.	Flow	cytometric	analysis	 showed	
that	upon	release	 from	the	HU-block,	 the	
HCT116+chr3	cells	were	clearly	 slower	 in	
their	progression	through	S-phase,	whereas	
the	 HCT116	 cells	 accumulated	 at	 G2/M	
(Fig.	3A,	20–24	h	+	CDDP).	Accordingly,	
phosphorylation	 of	 histone	 H3	 was	 only	
detectable	 in	 HCT116	 (Fig.	 3B	 and	
Supplementary	 Fig.	 1).	 This	 confirmed	
that	 mismatch	 repair-proficient	 cells	 were	
blocked	 in	 late	 S-/early	 G2-phase.	 The	
presence	of	a	sub-G1	peak	in	HCT116+chr3	
cells	 from	 20	 h	 of	 treatment	 onward	
indicated	 that	 exit	 from	the	cell	 cycle	 and	
the	triggering	of	cell	death	was	rapid,	likely	
due	to	the	inability	to	bypass	the	block.	At	later	times	post-treatment	
(48–72	h),	apoptosis	was	evident	in	both	cell	 lines,	as	 indicated	by	
the	 sub-G1	 peak	 in	 the	 flow	 cytometric	 profiles	 (Fig.	 3A)	 and	 the	
degradation	 of	 cellular	 proteins	 such	 as	 Cdk1	 (Fig.	 3B),	 which	 is	
representative	of	proteins	that	are	expressed	throughout	the	cell	cycle.	
As	further	support	for	the	fact	that	the	HCT116+chr3	cells	displayed	
a	genuine	S-phase	delay	 in	response	to	cisplatin,	only	 in	these	cells	
could	we	detect	distinct	PCNA	foci,	an	indication	of	ongoing	DNA	
replication,	 whereas	 the	 MMR-deficient	 HCT116	 cells	 displayed	
diffuse	PCNA	staining,	typical	of	cells	that	have	concluded	S-phase	
(Fig.	 3C).	 The	 S-phase	 delay	 was	 quantified	 by	 measuring	 the	
incorporation	 of	BrdU	 into	nascent	DNA:	 the	 data	 indicated	 that	
HU-released	 HCT116+chr3	 cells	 delayed	 their	 transition	 through	
S-phase	by	~4	h	in	response	to	cisplatin	(maximal	BrdU	incorpora-
tion	 at	 22	 h),	 as	 compared	 to	 the	MMR-deficient	HCT116	 cells	
(maximal	BrdU	incorporation	at	18	h)	(Supplementary	Fig.	2).	Foci	
of	g-H2AX	were	detected	 in	both	 cell	 lines,	 though	 they	 appeared	
to	be	larger	in	the	HCT116+chr3	cells	(Fig.	3C).	In	contrast	to	the	
A2780/CP70	system,	both	HCT116	and	HCT116+chr3	remained	
permanently	arrested	at	G2/M	(Fig.	3A)	and	died	by	apoptosis	48-72	
h	 post-treatment.	HR	proteins	were	 not	 preferentially	 degraded	 in	
the	MMR-proficient	HCT116+chr3	cells,	but	disappeared	 in	both	
MMR-proficient	 and	 -deficient	 cells	 following	 the	 kinetics	 of	 cell	
death	(Fig.	2B).
Progression	of	cisplatin-treated	293T-La-/+	cells,	either	in	MMR-	
proficient	 or	 -deficient	 state,	 through	 the	 cell	 cycle	 (Fig.	 4A)	 and	
checkpoint	 activation	 in	 these	 cells	 (Fig.	 4B)	were	 similar	 to	 those	
observed	 in	 HCT116±chr3	 cells,	 except	 that	 the	 S-phase	 delay	
observed	 in	 the	 MMR-proficient	 HCT116+chr3	 cells	 was	 not	
evident	 in	 the	MMR-proficient	 293T-La+	 cells.	This	 is	 likely	 due	
to	the	fact	that,	among	other	possible	defects,	p53	in	the	latter	line	
has	been	inactivated	by	the	HPV	E6	and	the	SV40	large-T	antigens	
and	 could,	 therefore,	 not	 contribute	 with	 its	 S-phase	 checkpoint	
function.45
Taken	together,	the	evidence	obtained	in	our	study	suggests	that	
in	an	ovarian	cancer	model	(i.e.,	A2780)	as	well	as	in	the	semi-iso-
genic	 cell	 line	 HCT116+chr3,	 MMR	 proficiency	 correlates	 with	
the	 ability	of	 the	 cells	 to	 slow	down	 transition	 through	S-phase	 in	
response	to	cisplatin.	However,	whether	the	lack	of	S-phase	delay	in	
CP70	and	HCT116	depends	only	on	the	MMR	status	or	is	addition-
ally	 contributed	 to	 by	 the	 acquisition	 of	 other	 genetic	 alterations,	
cannot	be	established	at	 this	point.	Moreover,	 the	ability	 to	bypass	
the	G2/M	 checkpoint	 that	 accompanied	 cisplatin-resistance	 in	 the	
CP70	 cells	 examined	 in	 our	 study	 could	 not	 be	 attributed	 to	 the	
MMR-deficiency	 alone,	 since	 in	 the	 semi-isogenic	 HCT116	 cells	
and	 in	 the	 strictly	 isogenic	 setting	of	293T-La-/+	cells,	 such	bypass	
did	not	occur.
The	 A2780/CP70	 cell	 lines	 represent	 a	 relevant	 model,	 since	
resistance	to	cisplatin	in	these	cells	was	induced	through	a	selection	
process	similar	to	what	occurs	in	patients	undergoing	chemotherapy.	
In	this	system,	bypass	of	cisplatin-induced	cell	cycle	arrest	seemed	to	
correlate	with	the	maintenance	of	intact	homologous	recombination	
Figure 4. Cisplatin response of the strictly isogenic MMR‑deficient and –proficient 293T‑La‑/+ cells. 
(A) HU‑synchronized MMR‑proficient 293T‑La+ and MMR‑deficient 293T‑La‑ cells were treated with 
15 mM cisplatin and cell cycle progression was assessed by flow cytometry at the indicated times. 
(B) Western blot analyses of total cell extracts derived from the cells shown in (A).
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machinery,	 suggesting	 that	 the	 expression	pattern	of	 these	proteins	
could	be	used	in	the	course	of	therapy	for	the	diagnosis	of	emerging	
drug	resistance.	Furthermore,	our	data	suggest	that	future	therapeutic	
protocols	might	wish	to	take	advantage	of	the	finding	that	inactiva-
tion	of	the	homologous	recombination	machinery	sensitizes	cells	to	
the	drug.	Support	for	this	suggestion	can	be	drawn	from	knock-out	
studies	of	Rad51	paralogs	in	the	B-lymphocyte	DT40	model	system,	
where	 it	 was	 shown	 that	 defective	 recombination	 conferred	 high	
sensitivity	to	cross-linking	agents	such	as	mitomycin	C	or	cisplatin.46	
Thus,	 downregulation	 of	 recombination	 by,	 for	 example,	 siRNA	
technology,	 would	 not	 only	 provide	 a	 strategy	 complementary	 to	
the	proposed	 inactivation	of	NER	as	a	means	 to	 interfere	with	 the	
repair	of	cisplatin-induced	damage,47	but	would	also	counteract	the	
emergence	 of	 cisplatin	 resistance	 through	 promoting	 the	 massive	
apoptotic	response	observed	in	A2780	cells.
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